Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.
Tuija VäänänenKatriina VuolteenahoHannu KautiainenRiina NieminenTimo MöttönenPekka HannonenMarkku KorpelaMarkku J KauppiKari LaihoOili Kaipiainen-SeppänenRiitta LuosujärviTea UusitaloToini UutelaMarjatta Leirisalo-RepoEeva Moilanennull nullPublished in: PloS one (2017)
High YKL-40 levels were found to be associated with disease activity in early DMARD-naïve RA and during intensive treat-to-target therapy. The present results suggest YKL-40 as a useful biomarker of disease activity in RA to be used to steer treatment towards remission.